Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2013) 32 P75 | DOI: 10.1530/endoabs.32.P75


Theagenio Cancer Hospital, Thessaloniki, Greece.


Introduction: Women with non-metastatic breast cancer form a distinct subpopulation in which calcium homeostasis in response to treatment with denosumab has not been extensively investigated.

Methods: Female patients with osteoporosis, who were eligible for treatment with denosumab, were prospectively enrolled (2011–2012) and divided into two groups; Group A consisting of patients with either no history or benign diseases non affecting bone metabolism (n=24 controls) and Group B patients with non-metastatic breast cancer (n=18). Documentation of renal impairment, disorders of parathyroid function or the presence of bone metastases served as exclusion criteria. All patients were administered a single-dose of denosumab under standard calcium and vitamin D supplementation. Serum calcium, phosphorus, parathyroid hormone (iPTH) and 24 h urine calcium were measured at days 0, 7 and 180. Primary outcomes were the development of hypocalcaemia and secondary hyperparathyroidism.

Results: At baseline, groups were comparable in age, calcium and iPTH levels. No events of hypocalcaemia were recorded. Overall, incidence of secondary hyperparathyroidism was found to be 45.5% one week after administration of denosumab. Interestingly, at day 180 incidence of secondary hyperparathyroidism was higher in Group B in contrast to the pattern recorded in controls, although not reaching statistical significance. At day 7, iPTH was found to be significantly higher only in controls (Wilcoxon Signed Rank test: P=0.013) compared to group-specific baseline values. At day 180, borderline increase in iPTH of Group B was noted (P=0.08), whereas iPTH returned to baseline in controls.

Discussion: A pattern of delayed development of secondary hyperparathyroidism might be present in patients with non-metastatic breast cancer. It could be extrapolated that this finding might be associated with a partial functional defect in calcium sensing receptor, which has recently been implicated in the pathogenesis of breast cancer. The findings warrant further investigation.

Article tools

My recent searches

No recent searches.